Nykode Therapeutics AS Sustainability Reports
A clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company specializes in custom-built protein and DNA vaccines targeting antigens to antigen-presenting cells for oncology and autoimmune diseases.
Sector: Professional & technical services
Country: Norway
Exchange: Oslo Børs
LEI: 254900UKQHWYZJD22017
FIGI: BBG006GPJ0B0
10 reports from 2020 to 2025
